[
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Advances Cancer Treatments With Epcoritamab And Mirvetuximab Approvals",
    "summary": "Health Canada's recent approval of ELAHERE® for a challenging form of cancer marks a step forward for AbbVie (ABBV) in oncology, enhancing its presence in a high-need therapeutic area. Alongside this, the updated results presented from its EPCORE® NHL-6 trial further underscore the company's commitment to advancing treatments in oncology. Yet, despite these developments, AbbVie's stock price rise of 13% over the last quarter aligns closely with broader market trends, which have also seen...",
    "url": "https://finnhub.io/api/news?id=bb3d088cc316bd01391fe833b6a4b2f120df0f88af63f725318f51d57e225d4e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756924881,
      "headline": "AbbVie (ABBV) Advances Cancer Treatments With Epcoritamab And Mirvetuximab Approvals",
      "id": 136631129,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Health Canada's recent approval of ELAHERE® for a challenging form of cancer marks a step forward for AbbVie (ABBV) in oncology, enhancing its presence in a high-need therapeutic area. Alongside this, the updated results presented from its EPCORE® NHL-6 trial further underscore the company's commitment to advancing treatments in oncology. Yet, despite these developments, AbbVie's stock price rise of 13% over the last quarter aligns closely with broader market trends, which have also seen...",
      "url": "https://finnhub.io/api/news?id=bb3d088cc316bd01391fe833b6a4b2f120df0f88af63f725318f51d57e225d4e"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)",
    "summary": "AbbVie (NYSE: ABBV) today announced updated results from the Phase 2 EPCORE® NHL-6 trial (NCT05451810) evaluating the feasibility of dosing and monitoring patients in the outpatient setting for the first full dose of epcoritamab monotherapy, a T-cell engaging bispecific antibody administered subcutaneously, in adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have received at least one prior line of systemic therapy. Results from the study demonstrated that",
    "url": "https://finnhub.io/api/news?id=23fd712a3b9442503351e1fcbfa64dc5458ecd4cacf0728c47c355fc18ee7d05",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756906200,
      "headline": "AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)",
      "id": 136615683,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced updated results from the Phase 2 EPCORE® NHL-6 trial (NCT05451810) evaluating the feasibility of dosing and monitoring patients in the outpatient setting for the first full dose of epcoritamab monotherapy, a T-cell engaging bispecific antibody administered subcutaneously, in adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have received at least one prior line of systemic therapy. Results from the study demonstrated that",
      "url": "https://finnhub.io/api/news?id=23fd712a3b9442503351e1fcbfa64dc5458ecd4cacf0728c47c355fc18ee7d05"
    }
  },
  {
    "ts": null,
    "headline": "Allergan Aesthetics Launches Campaign to Educate Consumers about Hyaluronic Acid (HA) Injectable Fillers",
    "summary": "Allergan Aesthetics, an AbbVie company, has launched the \"Naturally You with Injectable Hyaluronic Acid Fillers\" campaign, aimed to providing clear, factual education about HA injectable fillers. This initiative focuses on correcting misinformation to elevate understanding and celebrate the safe, natural-looking outcomes possible with hyaluronic acid injectable fillers.",
    "url": "https://finnhub.io/api/news?id=12560b033311e24f3096e9fb4a045bc2bdc53537b8f2e6a5988133f288a6b785",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756904400,
      "headline": "Allergan Aesthetics Launches Campaign to Educate Consumers about Hyaluronic Acid (HA) Injectable Fillers",
      "id": 136615684,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Allergan Aesthetics, an AbbVie company, has launched the \"Naturally You with Injectable Hyaluronic Acid Fillers\" campaign, aimed to providing clear, factual education about HA injectable fillers. This initiative focuses on correcting misinformation to elevate understanding and celebrate the safe, natural-looking outcomes possible with hyaluronic acid injectable fillers.",
      "url": "https://finnhub.io/api/news?id=12560b033311e24f3096e9fb4a045bc2bdc53537b8f2e6a5988133f288a6b785"
    }
  }
]